GSK's Bepirovirsen Achieves Breakthrough Functional Cure Rates in Phase III Chronic Hepatitis B Trials
核心洞察
GSK announced positive results from two pivotal phase III trials (B-Well 1 and B-Well 2) evaluating bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (搜索) treatment in over 1,800 patients across 29 countries.
Bepirovirsen demonstrated statistically significant and clinically meaningful functional cure rates when combined with standard care, representing a potential breakthrough for a disease affecting more than 250 million people worldwide.
The drug could become the first finite six-month therapeutic option for chronic hepatitis B (搜索), compared to current treatments that typically require lifelong therapy with functional cure rates of only 1%.
GSK announced positive results from two pivotal phase III trials evaluating bepirovirsen, an investigational antisense oligonucleotide that demonstrated statistically significant functional cure rates for chronic hepatitis B (搜索) (CHB). The B-Well 1 and B-Well 2 trials, involving over 1,800 patients from 29 countries, met their primary endpoints and showed clinically meaningful improvements over current standard of care.
Trial Results and Clinical Significance
The global multi-centre, randomised, double-blind, placebo-controlled trials assessed bepirovirsen's efficacy in nucleos(t)ide analogue-treated participants with CHB and baseline surface antigen (HBsAg) ≤3000 IU/ml. Functional cure rates were significantly higher with bepirovirsen plus standard of care compared with standard of care alone, with results statistically significant across all ranked endpoints.
Particularly notable results emerged in patients with baseline surface antigen (HBsAg) ≤1000 IU/ml, where an even greater effect was demonstrated. The trials showed an acceptable safety and tolerability profile consistent with previous studies.
Functional cure for CHB is defined as sustained loss of hepatitis B surface antigen and undetectable hepatitis B virus DNA (搜索) for at least 24 weeks after a finite course of treatment. This allows the immune system to control the infection without further medication and is associated with significant reduction in the risk of long-term liver complications, including liver cancer (搜索), as well as all-cause mortality.
Addressing Critical Unmet Medical Need
Chronic hepatitis B (搜索) represents a major global health challenge, affecting more than 250 million people worldwide and causing approximately 1.1 million deaths each year. The disease accounts for approximately 56% of liver cancer (搜索) cases globally, making it the leading cause of liver cancer.
Current standard of care with nucleos(t)ide analogues (搜索) often requires lifelong therapy, with functional cure rates remaining disappointingly low at typically only 1%. Many patients need to stay on medication indefinitely for viral suppression, highlighting the critical need for more effective treatment approaches.
Mechanism of Action and Development
Bepirovirsen is a triple action investigational antisense oligonucleotide designed to recognise and orchestrate the destruction of the genetic components (RNA) of the hepatitis B virus. The drug inhibits viral DNA replication, suppresses hepatitis B surface antigen levels in the blood, and stimulates the immune system to increase chances of a durable and sustained response.
GSK licensed bepirovirsen from Ionis and collaborated on its development. The drug has received recognition from global regulatory authorities for its innovation and potential to address significant unmet need, including Fast Track designation from the US FDA, Breakthrough Therapy designation in China, and SENKU designation in Japan.
Regulatory Timeline and Future Implications
GSK plans to begin regulatory filings worldwide from the first quarter of 2026. Full results will be submitted for presentation at an upcoming scientific congress and published in a peer-reviewed journal to support regulatory submissions to health authorities globally.
If approved, bepirovirsen has the potential to become the first finite, six-month therapeutic option for CHB, representing a paradigm shift from current lifelong treatment approaches. The drug could also serve as a backbone for future sequential treatment strategies.
Tony Wood, Chief Scientific Officer at GSK, stated: "Bepirovirsen has the potential to transform treatment goals for people living with CHB by achieving significant functional cure rates – a first for the disease. Today's result supports our plans to progress bepirovirsen as a treatment and also continue its development as a backbone in future sequential therapies."